fulranumab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
fulranumab

GtoPdb Ligand ID: 8964

Synonyms: AMG-403 | JNJ-42160443

Compound class: Antibody

Comment: Fulranumab was an investigational, fully human IgG2κ monoclonal antibody targeting nerve growth factor (NGF) [1,6].
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record.
BLAST peptide sequence analysis reveals identical matches to peptide sequences submitted with patent US7601818 [9], which belong to antibody clone 4D4 therein.

References
1. Chang DS, Hsu E, Hottinger DG, Cohen SP. (2016) Anti-nerve growth factor in pain management: current evidence. J Pain Res, 9: 373-83. [PMID:27354823]
2. Hefti FF, Rosenthal A, Walicke PA, Wyatt S, Vergara G, Shelton DL, Davies AM. (2006) Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci, 27 (2): 85-91. [PMID:16376998]
3. Hill R. (2011) Blocking the effects of NGF as a route to safe and effective pain relief--fact or fancy?. Pain, 152 (10): 2200-1. [PMID:21719197]
4. Johnson & Johnson. Janssen Announces Discontinuation of Fulranumab Phase 3 Development Program in Osteoarthritis Pain. Accessed on 27/09/2019. Modified on 27/09/2019. Johnson & Johnson, https://www.jnj.com/media-center/press-releases/janssen-announces-discontinuation-of-fulranumab-phase-3-development-program-in-osteoarthritis-pain
5. Kelly KM, Sanga P, Zaki N, Wang S, Haeussler J, Louie J, Thipphawong J. (2019) Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies. Curr Med Res Opin, 35 (12): 2117-2127. [PMID:31387410]
6. Sanga P, Katz N, Polverejan E, Wang S, Kelly KM, Haeussler J, Thipphawong J. (2013) Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain. Pain, 154 (10): 1910-9. [PMID:23748114]
7. Sanga P, Katz N, Polverejan E, Wang S, Kelly KM, Haeussler J, Thipphawong J. (2017) Long-Term Safety and Efficacy of Fulranumab in Patients With Moderate-to-Severe Osteoarthritis Pain: A Phase II Randomized, Double-Blind, Placebo-Controlled Extension Study. Arthritis Rheumatol, 69 (4): 763-773. [PMID:27748055]
8. Slatkin N, Zaki N, Wang S, Louie J, Sanga P, Kelly KM, Thipphawong J. (2019) Fulranumab as Adjunctive Therapy for Cancer-Related Pain: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. J Pain, 20 (4): 440-452. [PMID:30368018]
9. Wild KD Jr, Treanor JJS, Huang H, Inoue H, Zhang TJ, Martin F. (2009) Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors. Patent number: US7601818 B2. Assignee: Amgen, Inc., Medarex, Inc.. Priority date: 15/07/2003. Publication date: 13/10/2009.

References

1. Chang DS, Hsu E, Hottinger DG, Cohen SP. (2016)
Anti-nerve growth factor in pain management: current evidence.
J Pain Res, 9: 373-83. [PMID:27354823]

2. Hefti FF, Rosenthal A, Walicke PA, Wyatt S, Vergara G, Shelton DL, Davies AM. (2006)
Novel class of pain drugs based on antagonism of NGF.
Trends Pharmacol Sci, 27 (2): 85-91. [PMID:16376998]

3. Hill R. (2011)
Blocking the effects of NGF as a route to safe and effective pain relief--fact or fancy?.
Pain, 152 (10): 2200-1. [PMID:21719197]

4. Johnson & Johnson.
Janssen Announces Discontinuation of Fulranumab Phase 3 Development Program in Osteoarthritis Pain.
Accessed on 27/09/2019. Modified on 27/09/2019. Johnson & Johnson, https://www.jnj.com/media-center/press-releases/janssen-announces-discontinuation-of-fulranumab-phase-3-development-program-in-osteoarthritis-pain

5. Kelly KM, Sanga P, Zaki N, Wang S, Haeussler J, Louie J, Thipphawong J. (2019)
Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies.
Curr Med Res Opin, 35 (12): 2117-2127. [PMID:31387410]

6. Sanga P, Katz N, Polverejan E, Wang S, Kelly KM, Haeussler J, Thipphawong J. (2013)
Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain.
Pain, 154 (10): 1910-9. [PMID:23748114]

7. Sanga P, Katz N, Polverejan E, Wang S, Kelly KM, Haeussler J, Thipphawong J. (2017)
Long-Term Safety and Efficacy of Fulranumab in Patients With Moderate-to-Severe Osteoarthritis Pain: A Phase II Randomized, Double-Blind, Placebo-Controlled Extension Study.
Arthritis Rheumatol, 69 (4): 763-773. [PMID:27748055]

8. Slatkin N, Zaki N, Wang S, Louie J, Sanga P, Kelly KM, Thipphawong J. (2019)
Fulranumab as Adjunctive Therapy for Cancer-Related Pain: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.
J Pain, 20 (4): 440-452. [PMID:30368018]

9. Wild KD Jr, Treanor JJS, Huang H, Inoue H, Zhang TJ, Martin F. (2009)
Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors.
Patent number: US7601818 B2. Assignee: Amgen, Inc., Medarex, Inc.. Priority date: 15/07/2003. Publication date: 13/10/2009.